Study wrapper · #938
The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities.
Ganamurali N, Sabarathinam S Clinical pharmacology in drug development. 2026.
DOI: 10.1002/cpdd.70001PubMed: 41545327
Editor's note
This perspective frames retatrutide as a significant advance in obesity pharmacotherapy, citing Phase 2 weight reductions and potential metabolic benefits. It is an opinion-oriented review rather than new trial data, and its framing is notably promotional, so it should be read with caution about tone. Included for the retatrutide narrative.
Plain-language abstract
A perspective article describing retatrutide, a triple hormone-receptor agonist studied for obesity, and the Phase 2 weight-loss results reported to date.
Related coverage
Supported
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
BMJ (Clinical research ed.)n=——2026
Weak / none
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.
Behavioural brain researchn=——2026
Supported
Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
High blood pressure & cardiovascular preventionn=——2026